“Just think that a Car-T (Chimeric Antigen Receptor T cell therapies, new personalized cancer therapies that act on the patient’s immune system to make it able to recognize and destroy cancer cells, ed) is produced individually for each patient by modifying its cells, compared to the classic chemically synthesized drug is an epochal revolution, the paradigm has changed for all the actors involved in the treatment process “. Thus Luigi Boano, vice president of Assobiotec-Federchimica, spoke during the webinar “Advanced therapies in Italy: today and tomorrow”, organized by the Higher Institute of Health and Assobiotec-Federchimica with the aim of improving interventions in all stages of advanced therapies.
“To improve access to advanced therapies, there is still a lot of work to be done – argued Boano – among the problems I note the lack of homogeneity in the national territory of centers specialized in treatments with advanced therapies, there is a substantial difference between the areas of the country and a consistent health migration to obtain treatment “.
#Boano #Assobiotec #Resolving #inequalities #access #advanced #therapies